Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dibenzyl trisulfide (DTS) is a naturally occurring organosulfur compound and secondary metabolite isolated from the plant *Petiveria alliacea* (commonly known as guinea hen weed or Anamú). It has been investigated for its immunomodulatory, antimalarial, and anticancer properties. In oncology, DTS acts as a small-molecule kinase inhibitor, selectively targeting ribosomal protein S6 kinase alpha-1 (RSK1) and modulating the mitogen-activated protein kinase (MAPK) signaling pathway (specifically ERK1/ERK2). It also induces lysosomal membrane permeabilization, leading to cathepsin B release and caspase-independent cell death in triple-negative breast cancer (TNBC) and other cancer types. Additionally, DTS has been shown to alter erythrocyte biophysical properties, increasing deformability and reducing *Plasmodium falciparum* invasion and adhesion, suggesting potential utility in malaria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dibenzyl trisulfide.